Table: Selected TLR Ligands in Clinical Trials
|CPG7909||TLR9||Coley Pharmaceutical Group||Lymphoma||I/II||CpG injections and radiotherapy |
|Coley/Pfizer||Metastatic breast cancer, renal cell cancer, T-cell lymphoma, non-small cell lung cancer, melanoma||I or II||CpG injection with or without chemotherapy |
|Ongoing and completed|
|Malaria||I||Malaria vaccine with and without CpG 7909 |
|CPG10101||TLR9||Coley Pharmaceutical Group||Hepatitis C||II||Pegylated interferon plus ribavirin with or without CPG 10101 in hepatitis C patients |
|1018 ISS||TLR9||Dynavax||Allergy||II||ISS conjugated to ragweed allergen given to patients with allergic rhinitis |
|B-cell follicular lymphoma||II||ISS given in conjunction with Rituxan |
|Metastatic colorectal cancer||I||ISS in combination with irinotecan and cetuximab |
|Hepatitis B||II||ISS with hepatitis B surface antigen compared with commercial hepatitis vaccine|
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!